Related Experiment Video
Updated: Aug 5, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Systemic Lupus Erythematosus and Pulmonary Hypertension
Konstantinos Parperis1, Nikolaos Velidakis1, Elina Khattab1
1Medical School, University of Cyprus, Nicosia CY2024, Cyprus.
Pulmonary Hypertension (PH) is common in Systemic Lupus Erythematosus (SLE), impacting survival. Early diagnosis and understanding its causes are crucial for effective treatment of SLE-related PH.
Area of Science:
- Rheumatology
- Cardiology
- Pulmonology
Background:
- Pulmonary Hypertension (PH) frequently complicates Systemic Lupus Erythematosus (SLE).
- PH in SLE can stem from immune dysregulation, cardiorespiratory issues, or thromboembolic diseases.
- Symptoms are often non-specific, including progressive dyspnea and fatigue.
Purpose of the Study:
- To emphasize the need for prompt diagnosis of SLE-related PH.
- To highlight the importance of identifying underlying pathogenetic mechanisms for targeted therapy.
- To underscore the negative impact of PH on SLE patient survival.
Main Methods:
- Review of clinical manifestations and pathogenetic mechanisms of PH in SLE.
- Comparison of management strategies for SLE-related PH with idiopathic pulmonary arterial hypertension (PAH).
- Assessment of current diagnostic tools and screening protocols for early detection.
Main Results:
- SLE-related PH presents with varied severity, from asymptomatic to life-threatening.
- Management often parallels that of idiopathic PAH.
- Specific diagnostic biomarkers or screening protocols for early detection are currently lacking.
Conclusions:
- Early diagnosis and understanding of pathogenetic mechanisms are vital for managing SLE-related PH.
- The presence of PH adversely affects survival rates in SLE patients.
- Further research is needed for specific diagnostic tools and targeted therapies.
More Related Videos
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:29Hypertension II: Pathophysiology
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: